BMEA
Biomea Fusion, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.01
+4.97%Aug 24, 2026, 20:05 UTC
Biomea Fusion Inc completed enrollment for its Phase II diabetes trial, a milestone for its lead metabolic drug program.
Source:Aug 13, 2026, 11:00 UTC
Biomea Fusion dosed the first patient in its OPAL study evaluating icovamenib in combination with semaglutide for obesity, assessing physical function, body weight, body composition, muscle health, and metabolic outcomes.
Source:Jun 5, 2026, 23:32 UTC
Biomea Fusion presented new clinical and translational data for icovamenib at the ADA 86th Scientific Sessions and announced expansion of its Phase I BMF-650 study.